Nabriva Therapeutics (NBRV) Releases Earnings Results, Beats Expectations By $0.03 EPS

Nabriva Therapeutics (NASDAQ:NBRV) issued its quarterly earnings data on Friday. The biotechnology company reported ($0.29) EPS for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.03, MarketWatch Earnings reports. The company had revenue of $1.70 million during the quarter, compared to the consensus estimate of $0.56 million. Nabriva Therapeutics had a negative net margin of 1,188.69% and a negative return on equity of 101.03%.

NASDAQ:NBRV traded up $0.24 during trading hours on Friday, reaching $2.67. The company’s stock had a trading volume of 1,447,857 shares, compared to its average volume of 1,745,594. The company has a market capitalization of $1.69 billion, a price-to-earnings ratio of -1.64 and a beta of 2.42. Nabriva Therapeutics has a 12 month low of $1.12 and a 12 month high of $6.05. The company has a quick ratio of 6.11, a current ratio of 6.11 and a debt-to-equity ratio of 0.35.

A number of equities analysts recently commented on the stock. Gabelli downgraded shares of Nabriva Therapeutics from a “buy” rating to a “sell” rating and set a $2.56 price objective for the company. in a research note on Wednesday, March 27th. ValuEngine downgraded shares of Nabriva Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, May 1st. HC Wainwright reissued a “buy” rating and issued a $7.00 price objective on shares of Nabriva Therapeutics in a research note on Thursday. Northland Securities set a $13.00 price objective on shares of Nabriva Therapeutics and gave the stock a “buy” rating in a research note on Wednesday. Finally, Zacks Investment Research downgraded shares of Nabriva Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, January 30th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and seven have given a buy rating to the company. Nabriva Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $8.25.

COPYRIGHT VIOLATION WARNING: This piece of content was first reported by Transcript Daily and is the sole property of of Transcript Daily. If you are reading this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this piece of content can be viewed at

Nabriva Therapeutics Company Profile

Nabriva Therapeutics plc, a clinical stage biopharmaceutical company, engages in the research and development of anti-infective agents to treat infections in humans. The company focuses on the pleuromutilin class of antibiotics. Its lead product candidate is lefamulin, which is in Phase III clinical trials in intravenous and oral formulations for the treatment of community-acquired bacterial pneumonia; and has completed Phase II clinical trials for the treatment of acute bacterial skin and skin structure infection.

See Also: What is Cost of Capital?

Earnings History for Nabriva Therapeutics (NASDAQ:NBRV)

Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with's FREE daily email newsletter.